Skip to main content
. Author manuscript; available in PMC: 2023 Aug 1.
Published in final edited form as: Cancer. 2022 Jun 1;128(15):2958–2966. doi: 10.1002/cncr.34269

Table 1.

Patient demographics.

Characteristics FOLFIRINOX GA Total

Total, N (%) 34 (49) 36 (51) 70 (100)
Age, Y, median 64 65 65
Gender, N (%)
 Male 16 (47) 21 (58) 37 (53)
 Female 18 (53) 15 (42) 33 (47)
Race, N (%)
 White 30 (88) 28 (78) 58 (83)
 Black 2 (6) 2 (6) 4 (6)
 Asian 0 (0) 5 (14) 5 (7)
 Other/unknown 2 (6) 1 (3) 3 (4)
ECOG PS, N (%)
 0 12 (35) 11 (31) 23 (33)
 1 22 (65) 24 (67) 46 (66)
 2 0 (0) 1 (3) 1 (1)
Primary site
 Head 10 (29) 12 (33) 22 (31)
 Body 8 (24) 14 (39) 22 (31)
 Tail 16 (47) 10 (28) 26 (37)
Metastasis site
 Liver 27 (79) 27 (75) 54 (77)
 Peritoneum 13 (38) 16 (44) 29 (41)
 Lung 4 (12) 7 (19) 11 (16)
 Other 1 (3) 3 (8) 4 (6)
Number of metastatic sites
 1 24 (71) 22 (61) 46 (66)
 2 9 (26) 11 (31) 20 (29)
 3 1 (3) 3 (8) 4 (6)